BioSpace News Archive

Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced updated preclinical data supporting development of the Company’s WEE1 inhibitor candidate, ATRN-1051, for the treatment of ovarian cancer.

Samsung Bioepis Co., Ltd. announced that it has entered into a commercialization agreement with Sandoz for SB17, a proposed biosimilar to Stelarai, marking a step forward in strengthening access to Samsung Bioepis’ immunology portfolio in the United States, Canada, European Economic Area, Switzerland and United Kingdom.

Sinovac Biotech Ltd. announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.

Visgenx, Inc. announced that the Company presented a poster on its synthetic AAV platform at the Cell and Gene Therapy: Advancing Next Generation Therapies, West Coast Symposium on September 7th in Brisbane, California.

ImmunityBio, Inc. announced that it has executed financing transactions resulting in approximately $200 million of proceeds to the Company through a financing including an exchange into equity of current debt and a new convertible debt instrument from Nant Capital, LLC, an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Founder, Executive Chairman and Global Chief Scientific and Medical Officer.

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer.

Intra-Cellular Therapies, Inc. today announced several CAPLYTA data presentations at the 2023 Psych Congress held September 6 - 10, 2023 in Nashville.

Avalyn Pharma Inc. announced the appointment of Melissa Rhodes, Ph.D., D.A.B.T to the newly created position of chief operating officer.

Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company announced a strategic reprioritization plan and its financial results for the second quarter ended June 30, 2023.

BioVie Inc. today announced that preliminary baseline data from its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer’s Disease.